HK Stock Market Move | JUNSHI BIO (01877) further rises by more than 5%, Tecentriq subcutaneous injection III clinical trial achieves main endpoints, plans to apply for market approval subsequently.

JUNSHI BIO (01877) rose by more than 5%, rising 4.43% to HK$25.48 as of the time of reporting, with a turnover of HK$46,147,700. On the news front, JUNSHI BIO announced that the company's independently developed Truprolide monoclonal antibody injection (subcutaneous injection) (product code: JS001sc) met the primary endpoint of a multicenter, open-label, randomized Phase III clinical study comparing Truprolide monoclonal antibody injection (product code: JS001) in combination with first-line chemotherapy for recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC). JUNSHI BIO plans to submit an application for the market approval of this product to regulatory authorities in the near future. Public information shows that JS001sc is a subcutaneous injection formulation developed by the company based on the already marketed Truprolide monoclonal antibody injection, making it the first domestically produced anti-PD-1 monoclonal antibody subcutaneous formulation to enter Phase III clinical studies, potentially bringing convenience in treatment for patients.